 Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had partnered with Celurlarity to develop an immunotherapy for solid tumours on Thursday, August 5. 